Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Increasingly Sensitive Genetic Testing Advances GI Cancer Diagnosis and Management

October 8th 2022

John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.

Neratinib Elicits Durable Responses in Metastatic or Recurrent HER2-Mutated Cervical Cancer

October 6th 2022

Single-agent neratinib produced robust responses in patients with metastatic or recurrent HER2-mutated cervical cancer, according to updated data from phase 2 SUMMIT basket trial.

Sapanisertib Gets FDA Fast Track Status for Pretreated NRF2-Mutated Squamous NSCLC

October 4th 2022

The FDA has granted a fast track designation to sapanisertib as a potential therapeutic option in patients with unresected or metastatic squamous non–small cell lung cancer whose tumors harbor an NRF2 mutation and who have previously received platinum-based chemotherapy and immune checkpoint inhibition.

FDA Green Lights Companion Diagnostic for Trastuzumab Deruxtecan in Metastatic HER2-Low Breast Cancer

October 4th 2022

The FDA has approved use of the PATHWAY anti-HER2/neu rabbit monoclonal primary antibody as a companion diagnostic to identify patients with HER2-low metastatic breast cancer who are eligible for treatment with trastuzumab deruxtecan.

FDA Approves Futibatinib for FGFR2+ Cholangiocarcinoma

September 30th 2022

The FDA has granted an accelerated approval to futibatinib (Lytgobi) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

FDA Greenlights Companion Diagnostic for Selpercatinib in RET+ NSCLC and Thyroid Cancers

September 29th 2022

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to select patients with RET fusion–positive locally advanced or metastatic non–small cell lung cancer, advanced or metastatic thyroid cancer, and advanced or metastatic medullary thyroid cancer who could be candidates to receive selpercatinib.

TAC01-HER2 Showcases Early Clinical Activity in HER2-Overexpressed Solid Tumors

September 25th 2022

TAC01-HER2 demonstrated early signals of clinical activity with a tolerable safety profile in patients with HER2-overexpressed solid tumors.

Clinical Trials Aim to Bring Zenocutuzumab to Patients with NRG1+ Cancers

September 22nd 2022

Blocking ligand interaction of HER2 and HER3 in patients with NRG1 fusion–positive tumors has demonstrated a clinically feasible avenue to improve outcomes with the novel agent zenocutuzumab.

FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion+ Solid Tumors

September 21st 2022

The FDA has granted accelerated approval to selpercatinib for adult patients with locally advanced or metastatic solid tumors harboring a RET gene fusion that have progressed on or after previous systemic treatment or who have no satisfactory alternative treatment options.

FDA Grants Regular Approval to Selpercatinib for Locally Advanced or Metastatic RET+ NSCLC

September 21st 2022

The FDA has granted a regular approval to selpercatinib (Retevmo) for adult patients with locally advanced or metastatic non–small cell lung cancer harboring a RET gene fusion, as detected by an FDA-approved test.

Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease

September 21st 2022

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

Pemigatinib Represents Transformative Treatment for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

September 13th 2022

Srdan Verstovsek, MD, PhD, discusses the clinical implications of the FDA approval of pemigatinib, the results of the FIGHT-203 trial, and the need to conduct chromosomal analysis for patients with myeloid/lymphoid neoplasms.

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12th 2022

Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.

DCC-3116 Displays Early Tolerability in RAS/RAF-Mutant Solid Tumors

September 11th 2022

The ULK1/2 inhibitor DCC-3116 was well tolerated as a monotherapy in patients with locally advanced or metastatic tumors harboring a RAS or RAF mutation.

ADP-A2M4CD8 Shows Promising Activity Across MAGE-A4+ Unresectable or Metastatic Tumor Types

September 10th 2022

An updated analysis of the phase 1 SURPASS trial showed that ADP-A2M4CD8, a next-generational autologous T-cell receptor designed to patients with solid tumors, may be an effective therapy in MAGE-A4-positive disease.

Taking Action to Individualize Ovarian Cancer Care: Key Takeaways

September 7th 2022

In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.

Taking Action to Individualize Ovarian Cancer Care: Excitement Surrounding PARP Inhibition

August 31st 2022

In this fourth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss key developments made with PARP inhibitors in the ovarian cancer treatment paradigm.

FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

August 26th 2022

The FDA has approved pemigatinib (Pemazyre) for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and FGFR1 rearrangement.

Continued Emergence of Targeted Therapies Reinforces Need for Frequent Genetic Testing in NSCLC

August 25th 2022

Although the efficacy of targeted agents and outcomes for patients with genetic mutations can vary, the availability of these treatments adds to the need for genetic testing across all patients with non–small cell lung cancer.

Investigators Validate Role of Liquid Biopsy in Predicting Chromosomal Abnormalities in Myeloid Neoplasms

August 24th 2022

Liquid biopsy using targeted next-generation sequencing for early diagnosis and monitoring of patients with myeloid neoplasms is effective and detects chromosomal structural abnormalities.